Premium
Treatment of alcohol withdrawal symptoms in hospitalized patients
Author(s) -
Flygenring J.,
Hansen J.,
Holst B.,
Petersen E.,
Sørensen A.
Publication year - 1984
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1984.tb02511.x
Subject(s) - medicine , barbital , carbamazepine , randomized controlled trial , alcohol withdrawal syndrome , alcohol , anesthesia , psychiatry , epilepsy , biochemistry , chemistry
– Seventy‐two hospitalized patients with alcohol withdrawal symptoms were treated with either carbamazepine (Tegretol®) or barbital (Diemal) in a randomized, double‐blind trial. The dose of trial medication as well as the duration of treatment was individual, corresponding to the conventional treatment schedule. During the trial period daily records were kept of target withdrawal symptoms, global evaluation, the patient's subjective feeling and unwanted effects. Sixty patients completed the treatment successfully. The two treatment groups were homogeneous as regards patient characteristics, pre‐treatment disease severity and drop‐out rate. No statisticaly significant differences were found in efficacy between the two treatments, and both drugs were well tolerated. It is concluded that carbamazepine is a valuable alternative drug in the treatment of mild and moderate alcohol withdrawal symptoms.